PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric Adenocarcinoma
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of PD-1 antibody combined
with apatinib mesylate in patients with unresectable, local advanced recurrent or metastatic
serum AFP-elevated gastric adenocarcinoma, who have at least received first-line antitumor
therapy or whose standard treatment is intolerable.